| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vancomycin | 11 | 2022 | 273 | 4.660 |
Why?
|
| Anticoagulants | 14 | 2022 | 787 | 3.050 |
Why?
|
| Anti-Bacterial Agents | 18 | 2022 | 2992 | 2.850 |
Why?
|
| Acute Kidney Injury | 12 | 2022 | 739 | 2.570 |
Why?
|
| Anti-Arrhythmia Agents | 10 | 2021 | 226 | 2.360 |
Why?
|
| Gentamicins | 7 | 2018 | 90 | 2.330 |
Why?
|
| Heart Defects, Congenital | 20 | 2019 | 1697 | 2.290 |
Why?
|
| Infant | 68 | 2022 | 13310 | 2.060 |
Why?
|
| Intensive Care Units, Pediatric | 15 | 2019 | 441 | 2.020 |
Why?
|
| Child, Preschool | 70 | 2021 | 16273 | 1.890 |
Why?
|
| Enoxaparin | 4 | 2017 | 66 | 1.840 |
Why?
|
| Warfarin | 6 | 2015 | 152 | 1.830 |
Why?
|
| Antithrombins | 4 | 2019 | 74 | 1.800 |
Why?
|
| Infant, Newborn | 50 | 2022 | 8223 | 1.740 |
Why?
|
| Child | 81 | 2022 | 29154 | 1.610 |
Why?
|
| Retrospective Studies | 84 | 2022 | 37905 | 1.550 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2014 | 257 | 1.520 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2021 | 473 | 1.500 |
Why?
|
| Heparin | 7 | 2022 | 360 | 1.470 |
Why?
|
| Digoxin | 3 | 2015 | 63 | 1.460 |
Why?
|
| Obesity | 9 | 2018 | 2884 | 1.380 |
Why?
|
| Phenobarbital | 2 | 2019 | 48 | 1.340 |
Why?
|
| Critical Illness | 8 | 2019 | 714 | 1.330 |
Why?
|
| Cardiovascular Agents | 3 | 2015 | 128 | 1.270 |
Why?
|
| Heart-Assist Devices | 7 | 2020 | 1171 | 1.190 |
Why?
|
| Phenytoin | 2 | 2018 | 71 | 1.180 |
Why?
|
| Cardiac Surgical Procedures | 12 | 2019 | 1237 | 1.180 |
Why?
|
| Hospitals, Pediatric | 10 | 2019 | 773 | 1.170 |
Why?
|
| Vasodilator Agents | 4 | 2015 | 219 | 1.160 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2019 | 4938 | 1.150 |
Why?
|
| Adolescent | 59 | 2021 | 31252 | 1.140 |
Why?
|
| Drug Monitoring | 6 | 2017 | 333 | 1.130 |
Why?
|
| Male | 98 | 2022 | 123000 | 1.060 |
Why?
|
| Tachycardia, Supraventricular | 4 | 2014 | 84 | 1.050 |
Why?
|
| Diuretics | 6 | 2018 | 170 | 1.040 |
Why?
|
| Heart Failure | 11 | 2016 | 2516 | 1.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2020 | 581 | 1.000 |
Why?
|
| Acetaminophen | 3 | 2019 | 116 | 0.970 |
Why?
|
| Antihypertensive Agents | 3 | 2016 | 395 | 0.920 |
Why?
|
| Female | 94 | 2022 | 141928 | 0.910 |
Why?
|
| Cardiotonic Agents | 6 | 2014 | 151 | 0.890 |
Why?
|
| Critical Care | 4 | 2016 | 770 | 0.880 |
Why?
|
| Anti-Infective Agents | 3 | 2021 | 446 | 0.870 |
Why?
|
| Seizures | 2 | 2018 | 989 | 0.850 |
Why?
|
| Drug Utilization | 2 | 2021 | 179 | 0.850 |
Why?
|
| Creatinine | 13 | 2022 | 531 | 0.840 |
Why?
|
| Furosemide | 3 | 2018 | 41 | 0.840 |
Why?
|
| Humans | 125 | 2022 | 261506 | 0.840 |
Why?
|
| Diuresis | 4 | 2017 | 63 | 0.830 |
Why?
|
| Medication Adherence | 2 | 2018 | 492 | 0.830 |
Why?
|
| Near Drowning | 1 | 2021 | 21 | 0.780 |
Why?
|
| Drowning | 1 | 2021 | 31 | 0.780 |
Why?
|
| Kidney | 4 | 2018 | 2146 | 0.770 |
Why?
|
| Patient Readmission | 3 | 2016 | 548 | 0.770 |
Why?
|
| Antithrombin III | 2 | 2017 | 28 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2021 | 1303 | 0.740 |
Why?
|
| Patient Admission | 4 | 2016 | 220 | 0.730 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 84 | 0.730 |
Why?
|
| Nitroprusside | 3 | 2011 | 48 | 0.720 |
Why?
|
| Ketorolac | 2 | 2012 | 20 | 0.720 |
Why?
|
| Antipyretics | 1 | 2019 | 10 | 0.710 |
Why?
|
| Length of Stay | 7 | 2019 | 1900 | 0.710 |
Why?
|
| Metabolic Clearance Rate | 6 | 2019 | 231 | 0.710 |
Why?
|
| Flecainide | 2 | 2021 | 27 | 0.700 |
Why?
|
| Ibuprofen | 1 | 2019 | 56 | 0.690 |
Why?
|
| Body Temperature | 1 | 2019 | 158 | 0.670 |
Why?
|
| Body Weight | 9 | 2022 | 1293 | 0.670 |
Why?
|
| Ciprofloxacin | 2 | 2013 | 89 | 0.670 |
Why?
|
| Ideal Body Weight | 1 | 2018 | 8 | 0.660 |
Why?
|
| Health Information Systems | 2 | 2020 | 34 | 0.660 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 37 | 0.660 |
Why?
|
| Enalapril | 3 | 2014 | 20 | 0.660 |
Why?
|
| Texas | 17 | 2021 | 6311 | 0.650 |
Why?
|
| Heart Diseases | 3 | 2011 | 732 | 0.650 |
Why?
|
| Alprostadil | 2 | 2015 | 33 | 0.650 |
Why?
|
| Natriuretic Agents | 3 | 2007 | 31 | 0.630 |
Why?
|
| Fenoldopam | 2 | 2008 | 12 | 0.630 |
Why?
|
| Infusions, Intravenous | 8 | 2018 | 1382 | 0.630 |
Why?
|
| Databases, Factual | 10 | 2020 | 2218 | 0.620 |
Why?
|
| Heart Rate | 6 | 2018 | 737 | 0.620 |
Why?
|
| Pediatrics | 6 | 2022 | 1141 | 0.620 |
Why?
|
| Propensity Score | 2 | 2018 | 750 | 0.610 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 321 | 0.600 |
Why?
|
| Hypotension | 5 | 2019 | 210 | 0.600 |
Why?
|
| Sotalol | 2 | 2021 | 31 | 0.600 |
Why?
|
| Propranolol | 2 | 2014 | 156 | 0.600 |
Why?
|
| Chlorothiazide | 1 | 2016 | 12 | 0.590 |
Why?
|
| Hospitalization | 7 | 2018 | 2083 | 0.590 |
Why?
|
| Blood Pressure | 6 | 2019 | 1467 | 0.590 |
Why?
|
| Drug Interactions | 5 | 2021 | 553 | 0.590 |
Why?
|
| Nephrons | 1 | 2016 | 48 | 0.580 |
Why?
|
| Hypertension | 3 | 2016 | 1503 | 0.580 |
Why?
|
| Amiodarone | 2 | 2015 | 42 | 0.580 |
Why?
|
| Cation Exchange Resins | 1 | 2016 | 4 | 0.580 |
Why?
|
| Polystyrenes | 1 | 2016 | 32 | 0.570 |
Why?
|
| Thromboembolism | 1 | 2017 | 155 | 0.570 |
Why?
|
| Infusions, Parenteral | 2 | 2014 | 191 | 0.560 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 324 | 0.560 |
Why?
|
| Hospital Mortality | 8 | 2022 | 1274 | 0.550 |
Why?
|
| International Normalized Ratio | 3 | 2013 | 48 | 0.550 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 16 | 0.550 |
Why?
|
| Dexmedetomidine | 2 | 2014 | 85 | 0.550 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2014 | 323 | 0.540 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 521 | 0.540 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 672 | 0.530 |
Why?
|
| Fractures, Bone | 1 | 2018 | 291 | 0.530 |
Why?
|
| Hypnotics and Sedatives | 2 | 2014 | 218 | 0.520 |
Why?
|
| Age Factors | 10 | 2019 | 5377 | 0.520 |
Why?
|
| Pseudomonas Infections | 2 | 2013 | 156 | 0.510 |
Why?
|
| Models, Biological | 4 | 2021 | 3254 | 0.510 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2007 | 343 | 0.510 |
Why?
|
| Acetazolamide | 3 | 2018 | 36 | 0.510 |
Why?
|
| Hyperkalemia | 1 | 2016 | 79 | 0.510 |
Why?
|
| Aortic Coarctation | 1 | 2016 | 103 | 0.500 |
Why?
|
| Risk Factors | 20 | 2022 | 17523 | 0.500 |
Why?
|
| Potassium | 2 | 2016 | 329 | 0.500 |
Why?
|
| Overweight | 2 | 2015 | 484 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2014 | 598 | 0.480 |
Why?
|
| Postoperative Complications | 8 | 2019 | 5542 | 0.470 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 655 | 0.470 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 76 | 0.460 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 180 | 0.460 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 46 | 0.450 |
Why?
|
| Cyanides | 2 | 2009 | 14 | 0.450 |
Why?
|
| Potassium Chloride | 1 | 2012 | 55 | 0.440 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 610 | 0.440 |
Why?
|
| Thrombosis | 3 | 2015 | 781 | 0.440 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.440 |
Why?
|
| Hypokalemia | 1 | 2012 | 55 | 0.430 |
Why?
|
| Time Factors | 14 | 2019 | 12926 | 0.430 |
Why?
|
| Body Mass Index | 3 | 2015 | 2203 | 0.430 |
Why?
|
| Medical Audit | 1 | 2013 | 188 | 0.420 |
Why?
|
| Anticonvulsants | 1 | 2015 | 431 | 0.420 |
Why?
|
| Cardiomyopathies | 3 | 2014 | 610 | 0.410 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 329 | 0.410 |
Why?
|
| Area Under Curve | 3 | 2019 | 700 | 0.410 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 384 | 0.410 |
Why?
|
| Down Syndrome | 1 | 2014 | 226 | 0.410 |
Why?
|
| Incidence | 11 | 2019 | 5673 | 0.410 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 162 | 0.400 |
Why?
|
| Anesthetics | 1 | 2012 | 115 | 0.400 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 846 | 0.400 |
Why?
|
| Case-Control Studies | 10 | 2018 | 6100 | 0.390 |
Why?
|
| Treatment Outcome | 24 | 2020 | 32848 | 0.380 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 4298 | 0.380 |
Why?
|
| Anesthesiology | 1 | 2012 | 138 | 0.380 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2012 | 137 | 0.380 |
Why?
|
| Immunologic Factors | 1 | 2014 | 649 | 0.370 |
Why?
|
| Blood Coagulation | 1 | 2011 | 185 | 0.370 |
Why?
|
| Linear Models | 6 | 2017 | 1085 | 0.370 |
Why?
|
| Drug Dosage Calculations | 3 | 2013 | 50 | 0.370 |
Why?
|
| Young Adult | 16 | 2020 | 21445 | 0.350 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 450 | 0.350 |
Why?
|
| Administration, Oral | 4 | 2018 | 1544 | 0.340 |
Why?
|
| Anesthesia | 1 | 2012 | 296 | 0.340 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 316 | 0.340 |
Why?
|
| Tertiary Care Centers | 4 | 2019 | 403 | 0.340 |
Why?
|
| Guideline Adherence | 1 | 2013 | 636 | 0.330 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2011 | 261 | 0.320 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 687 | 0.320 |
Why?
|
| Dopamine Agonists | 1 | 2008 | 85 | 0.320 |
Why?
|
| Cardiology | 1 | 2014 | 530 | 0.320 |
Why?
|
| United States | 11 | 2019 | 15433 | 0.310 |
Why?
|
| Pharmacy | 1 | 2007 | 15 | 0.310 |
Why?
|
| Adenosine A2 Receptor Agonists | 2 | 2018 | 18 | 0.310 |
Why?
|
| Alkalosis | 1 | 2007 | 28 | 0.310 |
Why?
|
| Logistic Models | 5 | 2018 | 3441 | 0.310 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2007 | 26 | 0.300 |
Why?
|
| Procainamide | 1 | 2006 | 13 | 0.300 |
Why?
|
| Chlorides | 1 | 2007 | 139 | 0.300 |
Why?
|
| Oliguria | 1 | 2006 | 18 | 0.290 |
Why?
|
| Half-Life | 3 | 2019 | 259 | 0.290 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2006 | 30 | 0.290 |
Why?
|
| Emergency Service, Hospital | 4 | 2018 | 1148 | 0.280 |
Why?
|
| Cohort Studies | 10 | 2020 | 9244 | 0.280 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2006 | 34 | 0.280 |
Why?
|
| Heart Transplantation | 7 | 2020 | 908 | 0.280 |
Why?
|
| Heart Ventricles | 1 | 2011 | 846 | 0.280 |
Why?
|
| Purines | 2 | 2018 | 273 | 0.270 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 994 | 0.270 |
Why?
|
| Intensive Care Units | 3 | 2021 | 717 | 0.270 |
Why?
|
| Factor Xa | 2 | 2017 | 26 | 0.270 |
Why?
|
| Captopril | 3 | 2014 | 34 | 0.250 |
Why?
|
| Shock, Septic | 1 | 2006 | 181 | 0.250 |
Why?
|
| Coronary Care Units | 3 | 2016 | 46 | 0.250 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 321 | 0.250 |
Why?
|
| Kidney Diseases | 4 | 2014 | 691 | 0.250 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 14889 | 0.250 |
Why?
|
| Vomiting | 2 | 2016 | 354 | 0.240 |
Why?
|
| Acute Disease | 4 | 2018 | 2422 | 0.230 |
Why?
|
| Respiration, Artificial | 2 | 2018 | 577 | 0.220 |
Why?
|
| Paraspinal Muscles | 1 | 2022 | 9 | 0.220 |
Why?
|
| Electrocardiography | 4 | 2015 | 1145 | 0.220 |
Why?
|
| Injections, Intravenous | 2 | 2016 | 573 | 0.220 |
Why?
|
| Nausea | 2 | 2015 | 525 | 0.210 |
Why?
|
| Hemodynamics | 5 | 2018 | 935 | 0.210 |
Why?
|
| Referral and Consultation | 1 | 2007 | 899 | 0.210 |
Why?
|
| Double Outlet Right Ventricle | 2 | 2011 | 17 | 0.200 |
Why?
|
| Blood Urea Nitrogen | 3 | 2006 | 95 | 0.200 |
Why?
|
| Amoxicillin | 1 | 2021 | 106 | 0.190 |
Why?
|
| Renal Replacement Therapy | 1 | 2022 | 135 | 0.190 |
Why?
|
| Residence Characteristics | 3 | 2021 | 348 | 0.190 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 249 | 0.190 |
Why?
|
| Ireland | 1 | 2020 | 30 | 0.190 |
Why?
|
| Cystic Fibrosis | 1 | 2003 | 264 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 2315 | 0.190 |
Why?
|
| Nerve Block | 1 | 2022 | 176 | 0.190 |
Why?
|
| Germany | 1 | 2020 | 111 | 0.190 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 2195 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2016 | 661 | 0.180 |
Why?
|
| Factor Xa Inhibitors | 3 | 2022 | 70 | 0.180 |
Why?
|
| Respiratory Paralysis | 1 | 2019 | 8 | 0.180 |
Why?
|
| Gestational Age | 2 | 2018 | 1069 | 0.180 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 52 | 0.180 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2013 | 218 | 0.180 |
Why?
|
| Drug Overdose | 2 | 2013 | 81 | 0.180 |
Why?
|
| Myocarditis | 2 | 2013 | 190 | 0.170 |
Why?
|
| Adult | 16 | 2022 | 77950 | 0.170 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2019 | 22 | 0.170 |
Why?
|
| Nafcillin | 1 | 2018 | 12 | 0.170 |
Why?
|
| Weight Gain | 2 | 2013 | 464 | 0.170 |
Why?
|
| Asthma | 2 | 2017 | 871 | 0.170 |
Why?
|
| Clindamycin | 1 | 2018 | 50 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2018 | 1471 | 0.170 |
Why?
|
| Hematocrit | 1 | 2018 | 142 | 0.160 |
Why?
|
| Outpatients | 1 | 2021 | 462 | 0.160 |
Why?
|
| Diaphragm | 1 | 2019 | 181 | 0.160 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 19 | 0.160 |
Why?
|
| Hospital Costs | 2 | 2019 | 228 | 0.160 |
Why?
|
| Bupivacaine | 1 | 2018 | 68 | 0.160 |
Why?
|
| Drug Evaluation | 1 | 2018 | 425 | 0.160 |
Why?
|
| Metolazone | 1 | 2017 | 5 | 0.160 |
Why?
|
| Computer Simulation | 2 | 2022 | 1529 | 0.160 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 71 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2020 | 243 | 0.160 |
Why?
|
| Hospital Charges | 1 | 2018 | 75 | 0.160 |
Why?
|
| Serum Albumin | 1 | 2018 | 257 | 0.160 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 126 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2017 | 22 | 0.150 |
Why?
|
| Syringes | 1 | 2017 | 42 | 0.150 |
Why?
|
| Esophageal Atresia | 1 | 2018 | 48 | 0.150 |
Why?
|
| Marfan Syndrome | 1 | 2019 | 142 | 0.150 |
Why?
|
| Busulfan | 1 | 2021 | 764 | 0.150 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 193 | 0.150 |
Why?
|
| Drug Utilization Review | 2 | 2014 | 36 | 0.150 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2018 | 67 | 0.150 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 163 | 0.150 |
Why?
|
| Mitral Valve | 1 | 2019 | 271 | 0.150 |
Why?
|
| Conscious Sedation | 1 | 2018 | 104 | 0.150 |
Why?
|
| Spinal Fusion | 1 | 2018 | 149 | 0.150 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 980 | 0.150 |
Why?
|
| Epinephrine | 1 | 2017 | 255 | 0.140 |
Why?
|
| Administration, Rectal | 1 | 2016 | 13 | 0.140 |
Why?
|
| Kidney Function Tests | 2 | 2008 | 192 | 0.140 |
Why?
|
| Hirudins | 2 | 2014 | 65 | 0.140 |
Why?
|
| Body Composition | 1 | 2019 | 595 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 1323 | 0.140 |
Why?
|
| Azithromycin | 1 | 2016 | 78 | 0.140 |
Why?
|
| Fever | 1 | 2019 | 497 | 0.140 |
Why?
|
| Cardiac Output, Low | 2 | 2007 | 81 | 0.140 |
Why?
|
| Hemorrhage | 2 | 2014 | 712 | 0.140 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 75 | 0.140 |
Why?
|
| Birthing Centers | 1 | 2015 | 10 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 308 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 622 | 0.140 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 364 | 0.140 |
Why?
|
| Peptide Fragments | 2 | 2014 | 1271 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 108 | 0.130 |
Why?
|
| Solubility | 1 | 2015 | 242 | 0.130 |
Why?
|
| Allergens | 1 | 2017 | 247 | 0.130 |
Why?
|
| Thinness | 1 | 2015 | 82 | 0.130 |
Why?
|
| Air Pollutants | 1 | 2017 | 139 | 0.130 |
Why?
|
| Institutional Practice | 1 | 2014 | 6 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2019 | 581 | 0.130 |
Why?
|
| Pipecolic Acids | 1 | 2014 | 13 | 0.130 |
Why?
|
| Pharmaceutical Solutions | 1 | 2014 | 22 | 0.120 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 49 | 0.120 |
Why?
|
| Tablets | 1 | 2014 | 53 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2011 | 554 | 0.120 |
Why?
|
| Drug Compounding | 1 | 2014 | 70 | 0.120 |
Why?
|
| Databases as Topic | 1 | 2014 | 133 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 285 | 0.120 |
Why?
|
| Morbidity | 1 | 2015 | 397 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 546 | 0.120 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 219 | 0.120 |
Why?
|
| Software | 2 | 2021 | 1321 | 0.120 |
Why?
|
| Infant, Premature | 4 | 2014 | 787 | 0.120 |
Why?
|
| Biological Availability | 1 | 2014 | 214 | 0.120 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 56 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 860 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2017 | 291 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 68 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2012 | 2307 | 0.120 |
Why?
|
| Chylothorax | 1 | 2013 | 36 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 602 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2014 | 205 | 0.110 |
Why?
|
| Ofloxacin | 1 | 2013 | 41 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 563 | 0.110 |
Why?
|
| Citalopram | 1 | 2013 | 36 | 0.110 |
Why?
|
| Levofloxacin | 1 | 2013 | 57 | 0.110 |
Why?
|
| Analgesics | 1 | 2016 | 390 | 0.110 |
Why?
|
| Liver Function Tests | 1 | 2013 | 173 | 0.110 |
Why?
|
| Nutritional Support | 1 | 2013 | 80 | 0.110 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 50 | 0.110 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 342 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2014 | 587 | 0.110 |
Why?
|
| Medical Records | 2 | 2011 | 415 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 460 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 301 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 544 | 0.110 |
Why?
|
| Medicaid | 1 | 2015 | 279 | 0.110 |
Why?
|
| Anorexia | 1 | 2013 | 143 | 0.110 |
Why?
|
| Fasting | 1 | 2014 | 349 | 0.110 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 595 | 0.110 |
Why?
|
| Diarrhea | 1 | 2016 | 686 | 0.110 |
Why?
|
| Postoperative Care | 2 | 2013 | 739 | 0.110 |
Why?
|
| Age of Onset | 1 | 2014 | 827 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2016 | 358 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 318 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 368 | 0.100 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2011 | 16 | 0.100 |
Why?
|
| Patient Care | 1 | 2012 | 149 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 289 | 0.100 |
Why?
|
| Preoperative Period | 1 | 2012 | 344 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 233 | 0.100 |
Why?
|
| Contraindications | 1 | 2011 | 150 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 998 | 0.100 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2011 | 66 | 0.100 |
Why?
|
| Ventilator Weaning | 1 | 2011 | 32 | 0.100 |
Why?
|
| Arginine | 1 | 2014 | 500 | 0.100 |
Why?
|
| Labetalol | 1 | 2011 | 12 | 0.100 |
Why?
|
| Aspirin | 2 | 2012 | 455 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7702 | 0.100 |
Why?
|
| Serum | 1 | 2011 | 68 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 2927 | 0.100 |
Why?
|
| Tobramycin | 1 | 2010 | 21 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2019 | 6869 | 0.090 |
Why?
|
| Candidiasis | 1 | 2013 | 262 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2013 | 213 | 0.090 |
Why?
|
| Amikacin | 1 | 2010 | 34 | 0.090 |
Why?
|
| Fontan Procedure | 1 | 2012 | 155 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 4988 | 0.090 |
Why?
|
| Thiocyanates | 1 | 2009 | 17 | 0.090 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2011 | 182 | 0.090 |
Why?
|
| Genome, Viral | 1 | 2010 | 155 | 0.090 |
Why?
|
| Nitric Oxide Donors | 1 | 2009 | 51 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 418 | 0.090 |
Why?
|
| Methemoglobinemia | 1 | 2009 | 18 | 0.090 |
Why?
|
| Hydrocortisone | 2 | 2014 | 388 | 0.090 |
Why?
|
| Dopamine | 2 | 2014 | 312 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 3472 | 0.080 |
Why?
|
| Sex Factors | 1 | 2014 | 2139 | 0.080 |
Why?
|
| Partial Thromboplastin Time | 2 | 2022 | 55 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2013 | 479 | 0.080 |
Why?
|
| Reoperation | 1 | 2013 | 1382 | 0.080 |
Why?
|
| Acid-Base Imbalance | 1 | 2008 | 30 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 1371 | 0.080 |
Why?
|
| Acidosis | 1 | 2009 | 116 | 0.080 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2008 | 36 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2013 | 2316 | 0.080 |
Why?
|
| Acecainide | 1 | 2006 | 2 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 787 | 0.070 |
Why?
|
| Sodium Bicarbonate | 1 | 2007 | 59 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2011 | 558 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2006 | 244 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2007 | 118 | 0.070 |
Why?
|
| Sepsis | 1 | 2012 | 652 | 0.070 |
Why?
|
| Biomarkers | 3 | 2014 | 5047 | 0.070 |
Why?
|
| Milrinone | 1 | 2006 | 33 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2006 | 95 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2010 | 834 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2011 | 620 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 414 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2014 | 1823 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 2403 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 829 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 6550 | 0.060 |
Why?
|
| Medical Errors | 1 | 2006 | 219 | 0.060 |
Why?
|
| Palliative Care | 2 | 2013 | 2037 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 1225 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 461 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2021 | 929 | 0.050 |
Why?
|
| Pharmacokinetics | 1 | 2021 | 42 | 0.050 |
Why?
|
| Prognosis | 3 | 2014 | 21713 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 2803 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 462 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2021 | 359 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 1546 | 0.050 |
Why?
|
| Heart | 2 | 2018 | 1223 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2009 | 12873 | 0.040 |
Why?
|
| Skin Temperature | 1 | 2019 | 32 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 485 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 4320 | 0.040 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 124 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2017 | 105 | 0.040 |
Why?
|
| Ozone | 1 | 2017 | 33 | 0.040 |
Why?
|
| Liposomes | 1 | 2018 | 684 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2017 | 86 | 0.040 |
Why?
|
| Penicillins | 1 | 2016 | 143 | 0.030 |
Why?
|
| Documentation | 1 | 2018 | 207 | 0.030 |
Why?
|
| Air Pollution | 1 | 2017 | 87 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2016 | 148 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 269 | 0.030 |
Why?
|
| Exercise Test | 1 | 2016 | 312 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 130 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1972 | 0.030 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2014 | 14 | 0.030 |
Why?
|
| Dobutamine | 1 | 2014 | 54 | 0.030 |
Why?
|
| Vasopressins | 1 | 2014 | 62 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 953 | 0.030 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2014 | 35 | 0.030 |
Why?
|
| Thoracic Duct | 1 | 2013 | 16 | 0.030 |
Why?
|
| Bradycardia | 1 | 2014 | 70 | 0.030 |
Why?
|
| Meningitis | 1 | 2014 | 112 | 0.030 |
Why?
|
| Pleurodesis | 1 | 2013 | 71 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2013 | 21 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 193 | 0.030 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2013 | 140 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 4758 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 660 | 0.030 |
Why?
|
| Octreotide | 1 | 2013 | 118 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2013 | 86 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 318 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2014 | 213 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 2014 | 245 | 0.030 |
Why?
|
| Candida | 1 | 2013 | 164 | 0.030 |
Why?
|
| Heterotaxy Syndrome | 1 | 2012 | 63 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Nicardipine | 1 | 2011 | 14 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2012 | 155 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 133 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2013 | 448 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 1085 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1301 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 15193 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4314 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2007 | 60 | 0.020 |
Why?
|
| Renin | 1 | 2007 | 92 | 0.020 |
Why?
|
| Aldosterone | 1 | 2007 | 72 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 502 | 0.020 |
Why?
|
| Middle Aged | 1 | 2014 | 86204 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2008 | 183 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2007 | 272 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 1062 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2010 | 764 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 191 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 2352 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9180 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 3203 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2006 | 577 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 467 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 3260 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8865 | 0.010 |
Why?
|
| Stents | 1 | 2008 | 1096 | 0.010 |
Why?
|
| Aging | 1 | 2010 | 1582 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 4892 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 6009 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.010 |
Why?
|